"MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma" by David J. Andorsky

Article

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

Blood (2016)

David J. Andorsky, Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO
Abdulraheem Yacoub, University of Kansas
Jacob D. Bitran, Oncology Specialists, SC, Park Ridge, IL
Jason Melear, Texas Oncology
Heather D. Brooks, Oncology and Hematology Associates, US Oncology Research, Roanoke, VA
Kenneth A. Foon, Celgene
Syed Rizvi, Celgene
Mary Llorente, Celgene
Jiahui Li, Celgene
Jeff P. Sharman, Willamette University

Link

Disciplines

Publication Date

December 2, 2016

DOI

10.1182/BLOOD.V128.22.1798.1798

Citation Information

David J. Andorsky, Abdulraheem Yacoub, Jacob D. Bitran, Jason Melear, et al.. "MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma" Blood Vol. 128 Iss. 22 (2016) p. 1798 - 1798
Available at: http://works.bepress.com/heather-brooks2/1/